Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00077636 · ClinicalTrials.gov registry record · Phase 4
ACCELERATE Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.
A Phase 4 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,469
- Enrollment target
NCT00077636 is a Phase 4 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 1,469 participants.
The verdict
NCT00077636, a Phase 4 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,469 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy and safety of different durations of treatment with PEGASYS combined with ribavirin in patients with CHC genotype 2 or 3 infection who have never previously received interferon (IFN) therapy. The anticipated time on study treatment is 3-12 months and the target sample size is 500+ individuals.
Interventions
- DRUG Copegus
- DRUG peginterferon alfa-2a [Pegasys]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,469 participants |
| Start Date | 2003-12 |
| Est. Completion | 2006-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00077636
The ClinicalTrials.gov registry entry for NCT00077636 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 1,469 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Copegus is the first listed.
NCT00077636 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00077636 about?
NCT00077636 is a clinical study titled "ACCELERATE Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.". This study will evaluate the efficacy and safety of different durations of treatment with PEGASYS combined with ribavirin in patients with CHC genotype 2 or 3 infection who have never previously received interferon (IFN) therapy. The anticipated time on study treatment is 3-12 months and the target ...
What is the current status of trial NCT00077636?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,469 participants. The study started on 2003-12. Estimated completion is 2006-03.
What interventions are being tested in trial NCT00077636?
The interventions under investigation include: Copegus (DRUG), peginterferon alfa-2a [Pegasys] (DRUG).
Who is sponsoring clinical trial NCT00077636?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.